menu
    • menu
    [{"orgOrder":0,"company":"VIB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Antibody-based drug","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VIB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"VIB \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"VIB \/ Not Applicable"},{"orgOrder":0,"company":"VIB","sponsor":"ExeVir Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Series A Financing","leadProduct":"VHH72-Fc antibody","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"VIB","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"VIB \/ VIB","highestDevelopmentStatusID":"5","companyTruncated":"VIB \/ VIB"},{"orgOrder":0,"company":"VIB","sponsor":"Surface Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SRF388","moa":"IL-27","graph1":"Oncology","graph2":"Phase I","graph3":"VIB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"VIB \/ VIB","highestDevelopmentStatusID":"6","companyTruncated":"VIB \/ VIB"},{"orgOrder":0,"company":"VIB","sponsor":"ExeVir Bio","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"XVR013","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VIB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"VIB \/ VIB","highestDevelopmentStatusID":"4","companyTruncated":"VIB \/ VIB"},{"orgOrder":0,"company":"VIB","sponsor":"Oxurion","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"THR-149","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"VIB","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"VIB \/ VIB","highestDevelopmentStatusID":"8","companyTruncated":"VIB \/ VIB"}]

    Find Clinical Drug Pipeline Developments & Deals by VIB

    Menu

    VIB

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            VIB

                            Belgium arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            VIB

                            Belgium arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THR-149

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Recipient : Oxurion

                            Deal Size : $32.4 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Oxurion Receives Upfront Payment of $400,000 Following Oncurious Asset License by VIB

                            Details : Under the agreement, VIB acquired Oxurion's preclinical oncology asset and will use the upfront in the development of THR-149, being evaluated in a Phase 2 clinical trial as a potential treatment for of diabetic macular edema.

                            Brand Name : THR-149

                            Molecule Type : Peptide

                            Upfront Cash : $0.4 million

                            July 24, 2023

                            Lead Product(s) : THR-149

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Recipient : Oxurion

                            Deal Size : $32.4 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            VIB

                            Belgium arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            VIB

                            Belgium arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XVR013

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : ExeVir Bio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19

                            Details : XVR013 targets a conserved region in the spike S2 subunit that is essential for viral entry. It neutralizes all previous and current variants of concern and the currently most frequently circulating variants, including XBB, XBB.1.5, BQ.1.1 and BF.7.

                            Brand Name : XVR013

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            March 13, 2023

                            Lead Product(s) : XVR013

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : ExeVir Bio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            VIB

                            Belgium arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            VIB

                            Belgium arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SRF388

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Surface Oncology

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of A...

                            Details : SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine, targets the rate-limiting p28 subunit of IL-27, and preclinical studies have shown that treatment with SRF388 blocks immunosuppressive biolog...

                            Brand Name : SRF388

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 19, 2022

                            Lead Product(s) : SRF388

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Surface Oncology

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            VIB

                            Belgium arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            VIB

                            Belgium arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VHH72-Fc antibody

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Recipient : ExeVir Bio

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            ExeVir Announces Close of US$50 million / EUR42 million Series A Financing

                            Details : Unique llama-derived VHH72-Fc antibody (XVR011) for potential treatment and prevention of Covid-19, ready to start first-in-human trials.

                            Brand Name : XVR011

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 16, 2021

                            Lead Product(s) : VHH72-Fc antibody

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Recipient : ExeVir Bio

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            VIB

                            Belgium arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            VIB

                            Belgium arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-based drug

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            VIB achieves important milestone in the development of a COVID-19 drug

                            Details : The team has now established that the antibody can neutralize a lab variant of the virus, an important step forward in the development of a potential antiviral drug against the new coronavirus.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 16, 2020

                            Lead Product(s) : Antibody-based drug

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth